March 3, 2026Open Access

Umbilical cord blood−derived natural killer cells as a viable and potent source for adoptive cell therapy

Key Points

UCB-derived natural killer cells show promise as a stable and effective source for immunotherapy in acute myeloid leukemia.
Cryopreserved natural killer cells from umbilical cord blood can be produced on a large scale for clinical use.
Rapid deployment of these cells may enhance treatment accessibility for patients with acute myeloid leukemia.
Scalability and standardization of UCB-derived NK cells call for further exploration in clinical settings.

Abstract

These findings support the feasibility of producing cryopreserved, UCB-derived NK cells as a stable and effective "off-the-shelf" product for adoptive immunotherapy, particularly in the treatment of acute myeloid leukemia, with advantages in scalability, standardization, and rapid clinical deployment.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Alves-Paiva et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69a767aebadf0bb9e87e1e90 — DOI: https://doi.org/10.1016/j.jcyt.2026.102079

Authors

Raquel de Melo Alves-Paiva

Larissa Leggieri Coa

Julia T. Cottas de Azevedo

Journals

Cytotherapy

Actions

Institutions

Hospital Israelita Albert Einstein

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Umbilical cord blood−derived natural killer cells as a viable and potent source for adoptive cell therapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion